Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

5.6%

1 terminated out of 18 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

56%

10 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed with results

Key Signals

86% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (1)
P 1 (3)
P 2 (1)
P 3 (10)

Trial Status

Completed6
Recruiting5
Unknown4
Active Not Recruiting2
Terminated1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT06756269Phase 2Recruiting

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

NCT06454175Phase 1Active Not Recruiting

A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

NCT06465914Phase 3Active Not RecruitingPrimary

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

NCT04422366Phase 3Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT04895020Phase 3Recruiting

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

NCT05518201Phase 1Completed

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

NCT05371353Recruiting

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

NCT05027776Phase 3Recruiting

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

NCT05372016Phase 3Completed

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT05584332Phase 3Terminated

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

NCT05580341Phase 3Unknown

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

NCT04425291Phase 3Completed

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT04905030Not ApplicableUnknown

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

NCT04796090Completed

Genital Wart and Sexuality in Adolescence

NCT03676101Phase 1Completed

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT04073082Unknown

Safety and Efficacy of Laser Therapy in Gynaecology

NCT03153566Phase 3UnknownPrimary

Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

NCT00999986Phase 3CompletedPrimary

Low Dose Cyclophosphamide Treats Genital Warts

Showing all 18 trials

Research Network

Activity Timeline